Skip to content

Driver-guided Ablation of Persistent Atrial Fibrillatiom

Driver-guided Ablation in the Treatment of Persistent Atrial Fibrillation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04085731
Enrollment
181
Registered
2019-09-11
Start date
2019-09-21
Completion date
2023-12-30
Last updated
2023-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Atrial Fibrillation

Brief summary

This is a prospective, single-center, study. A targeted number of 181patients with persistent AF will be included according to pre-defined criteria. The ablation procedure consists on the identification of the arrhythmic substrate using a novel integrated mapping technique. We hypothesize that such approach may potentially lead to a mechanisms-targeted ablation strategy of persistent AF.

Detailed description

This is a prospective, single-center, study enrolling a total of 181patients with persistent AF according to well defined inclusion and exclusion criteria. The ablation procedure consists on the identification of the arrhythmic substrate using a novel integrated 3D mapping technique followed by standard CPVA at the end of the procedure. We will ablate substrates showing fast and regular electrical activities, starting from areas with the fastest mean cycle length and/or areas that have consistent rotational or focal propagation pattern and/or areas that comprise the slow conduction zone of possible arrhythmia circuits. After substrate ablation and AF termination, arrhythmia inducibility will be assessed and, if not inducible, the procedure will be completed by standard CPVA. If AF is still inducible, a new 3D map will be performed to identify further targets to be eliminated. Electrical cardioversion may be done at the end of the procedure. We hypothesized that such approach may potentially lead to a mechanisms-targeted ablation strategy leading to elimination of arrhythmic sources in individual patients, thus improving their clinical outcome. We will also characterize, identify and target the real pathophysiological substrates. After ablation, AF recurrence will be assessed by implantable loop recorder or thans-telephonic ECG recording from the end of the 3 months blanking period to 12 months following the procedure.The duration of this study is expected to be 24 months, from the first patient enrollment to the last patient follow-up.

Interventions

PROCEDURECatheter ablation

Driver-guided catheter ablation of persistent atrial fibrillation

Sponsors

IRCCS Policlinico S. Donato
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Age (18-85 years), persistent AF according to ESC/EHRA guidelines, first or second ablation procedure, ability to provide informed written consent. \-

Exclusion criteria

Secondary AF, Hyperthyroidism, LVEF\<30%, NYHA functional class IV, uncorrected valvular heart diseases, contraindication to anticoagulation, left atrial thrombus, recent (\<6 months) myocardial infarction, thoracic surgery for congenital, valvular diseases, History of cerebrovascular events, pregnancy, cancer or other significant comorbidities. \-

Design outcomes

Primary

MeasureTime frameDescription
Freedom from any AF or atrial tachycardia assessed from the end of the months blanking period to 12 months after ablation.12 months after ablationAF recurrences will be documented by implantable loop recorder or trns-telephonic ECG recording

Secondary

MeasureTime frameDescription
Identification of electrophysiological substrateduring the procedureAreas with fast but regular activities or with consistent wave front propagation pattern, or with low P-P voltage, or complex fractionated electrograms
inducibility of AF after the procedureduring the procedureprogrammed atrial stimulation before and after isoproterenol
AF burden12 months after ablationAssessment of AF burden by trans-telephonic ECG recording or implantable loop recorder

Countries

Italy

Contacts

Primary ContactCarlo Pappone, MD
carlo.pappone@af-ablation.org+39 02 52774260
Backup ContactCarlo Pappone, MD
carlo.pappone@af-ablation.org+39 02 527742282

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026